

Systematic review and network meta-analysis of the risk of malignancy with biologic therapies and selective Janus kinase-1 inhibitors in atopic dermatitis

Daud Manzar¹, Nikhil Nair¹, Emmanuel Suntres², Myanca Rodrigues³, Logain Alghanemi^{4,5}, Mohannad Abu-Hilal⁴

¹Michael G. DeGroot School of Medicine, McMaster University, Hamilton, Ontario, Canada

²Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

³Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

⁴Division of Dermatology, McMaster University, Hamilton, Ontario, Canada

⁵Dermatology Department, King Abdulaziz University, Jeddah, Saudi Arabia

Adv Dermatol Allergol 2024; XLI (3): 270–275

DOI: <https://doi.org/10.5114/ada.2024.141125>

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease with multifactorial pathophysiology. Biologic therapies, including dupilumab (IL-4/IL-13 inhibitor) and tralokinumab (IL-13 inhibitor), as well as selective Janus kinase-1 (JAK-1) inhibitors such as upadacitinib and abrocitinib, have been approved for the treatment of moderate to severe AD. However, their association with the incidence of malignancy in AD patients remains uncertain.

Aim: We conducted a systematic review and network meta-analysis (NMA) to investigate and compare the incidence and risk of malignancy in individuals with moderate-to-severe AD treated with abrocitinib, upadacitinib, tralokinumab, or dupilumab.

Material and methods: Systematic searches were conducted in Ovid MEDLINE and EMBASE that included AD, malignancy, biologic and advanced therapies. The primary outcome was incidence of malignancy in AD patients receiving placebo or at least one of the following advanced therapies: dupilumab, tralokinumab, abrocitinib or upadacitinib. A random-effects NMA was conducted with odds ratios and a frequentist model.

Results: Our search identified 11 trials comprising 10097 patients. The NMA did not show any statistically significant association between dupilumab or selective JAK-1 inhibitors and the incidence of malignancy up to an average of 41 weeks of treatment.

Conclusions: Our analysis revealed no statistically significant increased risk of malignancy and no significant difference in the incidence of malignancy between selective JAK-1 inhibitors and dupilumab for the treatment of AD up to an average follow-up of 41 weeks. Nevertheless, further prospective studies with longer follow-up periods are warranted to confirm the safety of these therapies and their impact on the risk of malignancy.

Key words: cancer, malignancy, atopic dermatitis, eczema, dupilumab, Jak-inhibitor, biologic.

Introduction

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, xerosis, and erythematous papules and plaques [1]. AD is considered a type 2 immune-mediated disease and is often associated with other type 2 diseases like asthma and allergic rhinitis, as well as other conditions such as eosinophilic esophagitis, food allergies, prurigo nodularis and mental health disorders among others [1].

The relationship between AD and the risk of malignancy has been a topic of debate, with conflicting data on this association [2–4]. The increased risk of malignancy in AD patients could be attributed to various factors,

including chronic systemic inflammation, and the long-term use of immunosuppressive medications [2–4].

Recently, new advanced and targeted therapies have been approved for the treatment of moderate to severe AD such as dupilumab (IL-4/IL-13), tralokinumab (IL-13 inhibitor), and selective JAK-1 inhibitors such as upadacitinib and abrocitinib. These therapies target specific inflammatory pathways implicated in AD pathogenesis and have shown promising results in clinical trials.

IL-4 and IL-13 have been implicated positively and negatively in tumorigenesis. IL-4 has demonstrated oppositional effects on tumour development while also being implicated in the protection of tumour cells against apop-

Address for correspondence: Dr. Mohannad Abu-Hilal, Division of Dermatology, McMaster University, Hamilton, 1280 Main Street West, Hamilton, Ontario, Canada, e-mail: abuhilm@mcmaster.ca

Received: 22.12.2023, **accepted:** 5.02.2024, **online publication:** 30.06.2024.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license (<http://creativecommons.org/licenses/by-nc-sa/4.0/>)

tosis [5]. Similarly, IL-13 has been implicated in enhancing tumour metastasis [6, 7]. On the other hand, the JAK-STAT signalling pathways have shown anti-tumour properties, with STAT1 signalling exhibiting anti-tumorigenic, anti-metastatic, and tumour-suppressing effects while STAT3/STAT5 signalling exhibits tumorigenic, metastatic, and anti-apoptotic effects [8]. As a result, new advanced therapies targeting these molecules and pathways could play a role in enhancing or preventing carcinogenesis. Overall, given the potential risks of treatments, it is essential to understand their effects to ensure the best possible health outcomes. Therefore, this paper examines the risk of malignancy in patients with moderate to severe AD treated with IL-4/13 inhibitors and/or selective JAK-1 inhibitors.

Aim

To gain clarity on the association between biologic and selective JAK-1 therapies and the risk of malignancy in patients with AD, we conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials.

Material and methods

We performed a systematic review and NMA of randomized controlled trials of tralokinumab, dupilumab, abrocitinib, and upadacitinib for the treatment of moderate to severe AD.

Our study protocol was registered with the International Prospective Register of Systematic Reviews (CRD42022355839), and we followed the Preferred Reporting Items for Systematic Reviews and Network Meta-Analyses (PRISMA-NMA) guidelines [9].

Search strategy

We conducted systematic searches in Ovid MEDLINE and Embase from inception to 23 December 2022.

Eligibility criteria

The eligibility criteria included open label clinical trials, randomized controlled trials, and prospective cohort studies that examined AD patients treated with dupilumab, tralokinumab and selective JAK-1 inhibitors (abrocitinib and upadacitinib). There were no time limitations to this systematic review, however only studies originally in English were included. Studies reporting the incidence of malignancy in AD patients receiving these therapies were included for full-text screening. Ultimately, an article was included in the meta-analysis if it reported: 1) quantitative data on the incidence of malignancy in patients with AD and 2) had both a placebo/control group and an intervention group that included at least one of the eligible therapies (tralokinumab, dupilumab, abrocitinib, or upadacitinib).

Screening

Two reviewers (N.N. and D.M.) independently assessed the eligibility of all titles and abstracts. The most recent available study was included whenever duplicates were found. Full-text screening was performed by the same two reviewers (N.N. and D.M.) and any discrepancies during screening were resolved using a third reviewer (E.S.).

Data extraction

Two reviewers (N.N. and D.M.) independently extracted the data from the eligible studies into a standardized Microsoft Excel file. A third reviewer (E.S.) resolved any discrepancies that arose during data extraction. The extracted data included study design and characteristics (first author, date of publication), number, sex, age, incidence rate of malignancy in control and intervention groups and follow-up period.

Primary outcome

The primary outcome was the incidence of malignancy in patients treated with placebo or one of the advanced therapies mentioned above.

Risk of bias assessment

Risk of bias was assessed independently by two reviewers (D.M. and E.S.) using the Cochrane Risk of Bias Tool [10]. The following six domains were evaluated for having low, some concerns or high risk of bias: risk of bias arising from the randomization process, risk of bias due to deviations from the intended interventions, missing outcome data, risk of bias in measurement of the outcome, risk of bias in the selection of the reported result, and overall risk of bias. Discrepancies were resolved via reviewing studies in consensus.

Data synthesis

We conducted all analyses in Stata (StataCorp., Version 17) [11].

We performed a random-effects NMA using odds ratios (ORs) and 95% confidence intervals (CIs) to assess the association between different treatments and the incidence of malignancy. Our reference comparator was the placebo group.

We conducted random-effects, frequentist NMAs, i.e., multivariate meta-analysis, for the outcome, incidence of malignancy, assuming a common heterogeneity parameter [12, 13] with the *mvmeta* command [14, 15] and network suite in Stata. We first used the global test of the “design-by-treatment” model to check the coherence assumption in our entire network [16]. We then ran the node-splitting model to assess for incoherence between direct and indirect effect estimates. If incoherence was observed between direct and indirect effect estimates, we used the IF plot to assess loop-specific incoherence




Figure 1. PRISMA flowchart

[17]. Ranking probabilities for the interventions in our two networks were estimated using the surface under the cumulative ranking curve (SUCRA) values, mean ranks and rankograms [14, 17].

For the purposes of this analysis, different dosages of all agents were classified as unique interventions to evaluate any possible dose-dependent effects. Additionally, we combined arms for multi-arm trials which exam-




Figure 2. Network map showing the associations and their strengths between the various treatment groups, placebo and each other

ined the same intervention, by combining the number of patients and sample sizes across the respective arms.

Results

The literature search yielded 474 unique records. After screening titles and abstracts, 25 articles were retrieved for full-text evaluation; and 12 studies met the eligibility criteria. After screening, 11 were included in the analysis as shown in the PRISMA flow diagram (Figure 1).

Study characteristics

The studies included a combined total of 10097 patients with a mean age of 33.2 years and 57.4% male. The mean follow-up period of the studies was 41.4 weeks. Additional details of eligibility criteria and baseline characteristics are presented in Supplement 1.

Quality assessment

Based on the Cochrane Risk of Bias Tool [10], the methodological quality of most of the studies was intermediate to high, with most studies demonstrating either a low risk of bias or some concerns. A final judgment for each paper was then made for overall risk of bias. Discrepancies were resolved via reviewing studies in consensus. Some studies demonstrated a high risk of bias. The prospective cohort study was only included in the systematic review and not the NMA. Details of the quality assessments can be found in Supplement 2.

Incidence of malignancy

The NMA did not show any statistically significant difference in the incidence of malignancy between selective JAK-1 inhibitors and dupilumab when used to treat moderate to severe AD (Figures 2, 3). For all treatment groups, *p*-values were greater than 0.05 and the 95% confidence intervals in the forest plot had a lower bound of OR = 0.51 or less, demonstrating a lack of statistical significance (Figure 4). Furthermore, the confidence intervals were large demonstrating increased variability.

The network map has been included to demonstrate the comparisons between treatment groups and placebo. In our analysis, comparisons to placebo were the most frequent. Comparisons between different doses of abrocitinib and different doses of upadacitinib, as well as between abrocitinib 200 mg daily and various dupilumab doses, were also conducted (Table 1).

Discussion

We report a NMA examining the risk of malignancy in patients with moderate to severe AD treated with either dupilumab, upadacitinib or abrocitinib including data from 10097 patients in 11 separate trials. The results showed no statistically significant difference in the incidence of malignancy for selective JAK-1 inhibitors and

Upadacitinib 30 mg	Upadacitinib 15 mg	Dupilumab	Abrocitinib 200 mg	Abrocitinib 100 mg	Abrocitinib 10–30 mg	Placebo
Upadacitinib 30 mg	0.58 (0.24, 1.39)	1.43 (0.18, 10.98)	1.12 (0.12, 10.67)	0.51 (0.04, 6.25)	1.21 (0.06, 25.08)	0.63 (0.10, 4.18)
1.73 (0.72, 4.13)	Upadacitinib 15 mg	2.46 (0.29, 20.90)	1.93 (0.19, 20.01)	0.88 (0.07, 11.62)	2.08 (0.09, 45.95)	1.10 (0.15, 7.89)
0.70 (0.09, 5.41)	0.41 (0.05, 3.46)	Dupilumab	0.78 (0.20, 3.01)	0.36 (0.06, 2.16)	0.85 (0.07, 10.85)	0.45 (0.12, 1.69)
0.89 (0.09, 8.55)	0.52 (0.05, 5.39)	1.28 (0.33, 4.91)	Abrocitinib 200 mg	0.46 (0.08, 2.57)	1.08 (0.09, 12.46)	0.57 (0.13, 2.56)
1.96 (0.16, 23.94)	1.13 (0.09, 14.95)	2.79 (0.46, 16.79)	2.19 (0.39, 12.27)	Abrocitinib 100 mg	2.36 (0.19, 29.27)	1.24 (0.20, 7.72)
0.83 (0.04, 17.20)	0.48 (0.02, 10.59)	1.18 (0.09, 15.12)	0.93 (0.08, 10.67)	0.42 (0.03, 5.24)	Abrocitinib 10–30 mg	0.53 (0.04, 6.21)
1.58 (0.24, 10.38)	0.91 (0.13, 6.58)	2.25 (0.59, 8.53)	1.76 (0.39, 7.94)	0.81 (0.13, 5.00)	1.90 (0.16, 22.47)	Placebo

Figure 3. League table showing each treatment group compared to each other, demonstrating no statistically significant difference in incidence rate of malignancy in any treatment groups




Figure 4. Forest plot with odds ratios showing which of the treatment groups had a statistically significant difference in malignancy incidence when compared to placebo

dupilumab compared to placebo, and no significant difference between selective JAK-1 inhibitors and dupilumab when used to treat AD up to an average of 41 weeks of follow-up. This finding contrasts with concerns suggesting an increased risk of malignancy with JAK-1 inhibitors. While clinical observation and case reports have created the foundation for the hypothesis that JAK-1 inhibitors may have an increased risk of malignancy, our NMA has not demonstrated that.

Tofacitinib is a JAK 1,2,3 inhibitor and is approved for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, and juvenile idiopathic arthritis [18]. Tofacitinib has been shown to increase the risk of malignancy in RA patients over a period of 4 years with a hazard ratio of 1.48 when compared to patients treated with TNF- α inhibitors [19].

When considering the safety profile of abrocitinib and upadacitinib for the treatment of AD, it is essential to acknowledge potential variations between patient populations with RA and AD. For instance, individuals with RA may have a higher risk of developing malignancies, including lymphoma and lung cancer, compared to the general population [20]. These differences, along with the selectivity of upadacitinib and abrocitinib for JAK-1, and the relatively shorter mean follow-up period in the studies included in our NMA, may contribute to variations in outcomes between tofacitinib treatment for RA and our study. One other factor is the selectivity of upadacitinib and abrocitinib for JAK-1, unlike tofacitinib which is a JAK1,2,3 inhibitor. Other differences may be related to the shorter mean follow-up period seen in the studies included in our NMA compared to studies on tofacitinib.

Table 1. Surface under the cumulative ranking (SUCRA) curves showing the probabilities of each treatment being the treatment which causes the least incidence of malignancy

Treatment	SUCRA	Pr (Best)	Mean rank
Abrocitinib 100 mg	70.5	33.8	2.8
Upadacitinib 15 mg	68.1	31.7	2.9
Placebo	65.2	15	3.1
Upadacitinib 30 mg	41	2.3	4.5
Abrocitinib 10–30 mg	39.2	12.9	4.6
Abrocitinib 200 mg	38.9	3.5	4.7
Dupilumab	26.9	0.8	5.4

Proposed pathophysiological mechanisms for the relationship between various JAK inhibitors and malignancies suggest that the inhibition of specific JAK subtypes might impact natural killer cells' detection and subsequent elimination of certain malignancies [21]. Extended exposure to pharmacological agents inhibiting the JAK-STAT pathways may lead to prolonged immunologic dysfunction, particularly in natural killer cells, thereby potentially increasing the risk of malignancy in patients.

Malignancies may have a latent clinical presentation, making early detection challenging, and they may not be captured during the relatively short average follow-up period of 41 weeks in the included studies. It is possible that this duration is insufficient for the most commonly associated malignancies with JAK-1 inhibitor use to become clinically evident. Additionally, the doses and durations of JAK-1 inhibitor use in the studies may not have been long enough to induce a pro-inflammatory carcinogenic state that is easily detectable through symptomatic presentation or biomarker screenings. As a result, longer-term observational studies may provide more insights into this outcome than randomized controlled trials.

These results are very clinically pertinent as the belief that JAK-1 inhibitors are carcinogenic when used at specific doses and for certain time periods for AD has significantly influenced and guided clinical decision-making and practice. Our NMA aimed to discern whether these concerns are clinically warranted, and we discovered that at least in the short term (average follow-up of 41 weeks), JAK-1 inhibitors do not significantly increase the risk of malignancies when compared to dupilumab when used for AD.

However, it is crucial to acknowledge the limitations of this NMA. The small sample size ($n = 11$) restricted the assessment of the transitivity assumption and the examination of substantial heterogeneity observed through sub-group analyses and meta-regression. Despite these limitations, our study achieved coherence in both global and loop-specific instances of the network, highlighting the comparative effectiveness of the included interventions. Additionally, some trials included in our analysis had a high risk of bias, but their consistent results with other studies indicate that their impact on the overall robustness of results is unlikely to be significant. Fur-

thermore, our study could have been enhanced by including other biologic therapies falling within the IL-4/13 inhibitor and JAK-1 inhibitor categories used for AD treatment. Further research may be necessary to explore the incidence of cancer in other non-dupilumab IL-inhibitors and more JAK-1 inhibitors to gain a comprehensive understanding of the global effects of immunomodulatory therapy use for AD.

Conclusions

Based on our analysis, there was no statistically significant increased risk of malignancy and no significant difference in the incidence of malignancy between JAK-1 inhibitors and dupilumab when used for the treatment of AD up to an average follow-up of 41 weeks. These findings have important clinical implications, suggesting that perhaps clinicians should focus more on patient-centered outcomes when selecting advanced therapies for AD. Further research with longer follow-up periods and larger sample sizes may be needed to confirm these results and explore the effects of other biologic therapies in the context of AD.

Materials

Rayyan, also known as rayyan.ai, was used to conduct and complete the screening [22].

Google Sheets & Microsoft Excel were used to conduct extraction of all included papers.

Google Docs & Microsoft Word were used for the drafting and editing of the manuscript.

Stata was used to conduct the network meta-analysis and any other relevant statistical analyses [11].

The Prisma flow diagram and Prisma checklist was retrieved from <http://prisma-statement.org/> [9].

Zotero was used to facilitate the citation process.

CINeMA was used to assess confidence in the NMA results [23].

PROSPERO ID

CRD42022355839/

Acknowledgments

Daud Manzar, Nikhil Nair, Emmanuel Suntres – equal contributing authors.

Funding

Division of Dermatology, McMaster University, Hamilton, Ontario, Canada.

Ethical approval

Not applicable.

Conflict of interest

Daud Manzar, Nikhil Nair, Emmanuel Suntres, Myanca Rodrigues and Logain Alghanemi declare no conflicts of interest. Dr. Mohannad Abu-Hilal received honoraria, was a speaker and/or attended the advisory board for Galderma, Pfizer, Medexus, Janssen, Leo, Sanofi, Lilly AbbVie, Sun Pharma, L'Oreal and Novartis.

References

1. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. *J Allergy Clin Immunol* 2003; 112 (6, Suppl): S118-27.
2. Wang H, Diepgen T. Atopic dermatitis and cancer risk. *Br J Dermatol* 2006; 154: 205-10.
3. Jensen AO, Svaerke C, Körmendingé Farkas D, et al. Atopic dermatitis and risk of skin cancer. *Am J Clin Dermatol* 2012; 13: 29-36.
4. Arana A, Wentworth C, Fernández-Vidaurre C, et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. *Br J Dermatol* 2010; 163: 1036-43.
5. Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. *Cell Mol Immunol* 2009; 6: 415-22.
6. Little AC, Pathanjeli P, Wu Z, et al. IL-4/IL-13 stimulated macrophages enhance breast cancer invasion via rho-GTPase regulation of synergistic VEGF/CCL-18 signaling. *Front Oncol* 2019; 9: 456.
7. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13R 2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. *Int J Cancer* 2012; 131: 344-56.
8. Sabaawy HE, Ryan BM, Khiabani H, Pine SR. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. *Carcinogenesis* 2021; 42: 1411-9.
9. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; 372: n71.
10. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; 366: l4898.
11. StataCorp. Stata Statistical Software. College Station, TX: StataCorp LLC; 2021.
12. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 2012; 3: 111-25.
13. White IR. Network meta-analysis. *Stata J* 2015; 15: 951-85.
14. Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013; 8: e76654.
15. Chaimani A, Mavridis D, Salanti G. A hands-on practical tutorial on performing meta-analysis with Stata. *BMJ Ment Health* 2014; 17: 111-6.
16. Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 2012; 3: 98-110.
17. Chaimani A, Salanti G. Visualizing assumptions and results in network meta-analysis: the Network Graphs Package. *Stata J* 2015; 15: 905-50.
18. Dhillon S. Tofacitinib: a review in rheumatoid arthritis. *Drugs* 2017; 77: 1987-2001.
19. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med* 2022; 386: 316-26.
20. Parikh-Patel A, White RH, Allen M, Cress R. Risk of cancer among rheumatoid arthritis patients in California. *Cancer Causes Control* 2009; 20: 1001-10.
21. Nocturne G, Pascaud J, Ly B, et al. JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis. *Cell Mol Immunol* 2020; 17: 552-3.
22. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan – a web and mobile app for systematic reviews. *Syst Rev* 2016; 5: 210.
23. Nikolakopoulou A, Higgins JP, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. *PLoS Med* 2020; 17: e1003082.